Advertisement
CHRS ข่าวฟอเร็กซ์
Coherus Rolls Out YUSIMRY At $995 Per Carton In US
Coherus BioSciences, Inc. (CHRS) announced Monday that YUSIMRY (adalimumab-aqvh) is now available for commercial sale in the United States at a list price of $995 per carton for two 40 mg/0.8 mL autoinjectors.
RTTNews
|
684 วันที่ผ่านมา
Coherus, Junshi Biosciences Say FDA Accepts Resubmission Of Toripalimab BLA
Coherus BioSciences, Inc. (CHRS) and Shanghai Junshi Biosciences Co., Ltd. announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (NPC) and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy.
RTTNews
|
1046 วันที่ผ่านมา
